{"id":397628,"date":"2020-12-10T12:03:13","date_gmt":"2020-12-10T17:03:13","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=397628"},"modified":"2020-12-10T12:03:13","modified_gmt":"2020-12-10T17:03:13","slug":"gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/","title":{"rendered":"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital"},"content":{"rendered":"<p>        <!--.bwalignc { text-align: center; list-style-position: inside }body {font:normal small Arial,Helvetica,sans-serif;color:#000;background-color:#fff;padding:24px;margin:0;} a img {border:0;} h3 {font-size:medium;color:#000;margin:0 0 1em 0; text-align:center;}-->  <\/p>\n<p class=\"bwalignc\"><b>GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital<\/b><\/p>\n<p>PARIS&#8211;(<a href=\"http:\/\/www.businesswire.com\">BUSINESS WIRE<\/a>)&#8211;<br \/>\nRegulatory News:\n<\/p>\n<p>\nGenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the &#8220;<b>Company<\/b>&#8221; or &#8220;<b>GenSight<\/b>&#8220;), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces today that it has received, in connection with its bond agreement entered with Kreos Capital VI (Expert Fund) LP (&#8220;<b>Kreos<\/b>&#8220;), the notification by Kreos of (i) the conversion of 50% of the convertible bonds of tranches A and B (at a price of \u20ac2.245 per share), (ii) the conversion of 50% of the additional convertible bonds of tranche B (at a price of \u20ac2.574 per share) and (iii) the exercise of all share warrants of tranches A and B (at a price of \u20ac2.245 per share), representing a total issuance of 1,182,953 new ordinary shares.\n<\/p>\n<p>\nThe total number of shares of the Company that may be issued, in connection with the bond agreement, upon conversion of the remaining 50% of (i) the convertible bonds of tranches A and B (at a price of \u20ac2.245 per share) and (ii) the additional convertible bonds of tranche B (at a price of \u20ac2.574 per share) is 726,426 shares.\n<\/p>\n<p>\nThe new shares were listed on the regulated market of Euronext in Paris on December 10, 2020.\n<\/p>\n<p><b>About GenSight Biologics <\/b><\/p>\n<p>\nGenSight Biologics S.A. is a clinical-stage biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders. GenSight Biologics\u2019 pipeline leverages two core technology platforms, the Mitochondrial Targeting Sequence (MTS) and optogenetics, to help preserve or restore vision in patients suffering from blinding retinal diseases. Using its gene therapy-based approach, GenSight Biologics\u2019 product candidates are designed to be administered in a single treatment to each eye by intravitreal injection to offer patients a sustainable functional visual recovery. Developed as a treatment for Leber Hereditary Optic Neuropathy (LHON), GenSight Biologics\u2019 lead product candidate, LUMEVOQ<sup>\u00ae<\/sup> (GS010; lenadogene nolparvovec), is currently in the review phase of its registration process in Europe, and in Phase III to move forward to a BLA filing in the U.S.\n<\/p>\n<p><img decoding=\"async\" alt=\"\" src=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201210005824r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" style=\"width:0;height:0\" \/><span class=\"bwct31415\" \/><\/p>\n<p id=\"mmgallerylink\"><span id=\"mmgallerylink-phrase\">View source version on businesswire.com: <\/span><span id=\"mmgallerylink-link\"><a href=\"https:\/\/www.businesswire.com\/news\/home\/20201210005824\/en\/\" rel=\"nofollow\">https:\/\/www.businesswire.com\/news\/home\/20201210005824\/en\/<\/a><\/span><\/p>\n<p><b>GenSight Biologics<br \/>\n<\/b><br \/>Chief Financial Officer<br \/>\n<br \/>Thomas Gidoin<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:tgidoin@gensight-biologics.com\">tgidoin@gensight-biologics.com<br \/>\n<\/a><br \/>+33 (0)1 76 21 72 20\n<\/p>\n<p><b>LifeSci Advisors<br \/>\n<\/b><br \/>Investor Relations<br \/>\n<br \/>Guillaume van Renterghem<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:gvanrenterghem@lifesciadvisors.com\">gvanrenterghem@lifesciadvisors.com<br \/>\n<\/a><br \/>+41 (0)76 735 01 31\n<\/p>\n<p><b>RooneyPartners<br \/>\n<\/b><br \/>Media Relations<br \/>\n<br \/>Marion Janic<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:mjanic@rooneyco.com\">mjanic@rooneyco.com<br \/>\n<\/a><br \/>+1-646-537-5649\n<\/p>\n<p><b>Orpheon Finance<br \/>\n<\/b><br \/>Retail Investors<br \/>\n<br \/>James Palmer<br \/>\n<br \/><a rel=\"nofollow\" href=\"mailto:j.palmer@orpheonfinance.com\">j.palmer@orpheonfinance.com<br \/>\n<\/a><br \/>+33 (0)7 60 92 77 74\n<\/p>\n<p><b>KEYWORDS:<\/b> France Europe<\/p>\n<p><b>INDUSTRY KEYWORDS:<\/b> Health Other Health Clinical Trials Pharmaceutical Optical Biotechnology<\/p>\n<p><b>MEDIA:<\/b><\/p>\n<table cellpadding=\"3\" cellspacing=\"3\">\n<tr>\n<td><font face=\"Arial\" size=\"2\"><b>Logo<\/b><\/font><\/td>\n<\/tr>\n<tr>\n<td><img decoding=\"async\" src=\"https:\/\/mms.businesswire.com\/media\/20201210005824\/en\/666324\/3\/gensight-logo_RVB.jpg\" alt=\"Logo\" \/><\/td>\n<\/tr>\n<tr>\n<td><font face=\"Arial\" size=\"2\"><\/font><\/td>\n<\/tr>\n<\/table>\n","protected":false},"excerpt":{"rendered":"<p>GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital PARIS&#8211;(BUSINESS WIRE)&#8211; Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the &#8220;Company&#8221; or &#8220;GenSight&#8220;), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces today that it has received, in connection with its bond agreement entered with Kreos Capital VI (Expert Fund) LP (&#8220;Kreos&#8220;), the notification by Kreos of (i) the conversion of 50% of the convertible bonds of tranches A and B (at a price of \u20ac2.245 per share), (ii) the conversion of 50% of the additional convertible bonds of tranche B (at a price of \u20ac2.574 &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-397628","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital PARIS&#8211;(BUSINESS WIRE)&#8211; Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the &#8220;Company&#8221; or &#8220;GenSight&#8220;), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces today that it has received, in connection with its bond agreement entered with Kreos Capital VI (Expert Fund) LP (&#8220;Kreos&#8220;), the notification by Kreos of (i) the conversion of 50% of the convertible bonds of tranches A and B (at a price of \u20ac2.245 per share), (ii) the conversion of 50% of the additional convertible bonds of tranche B (at a price of \u20ac2.574 &hellip; Continue reading &quot;GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-12-10T17:03:13+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201210005824r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital\",\"datePublished\":\"2020-12-10T17:03:13+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/\"},\"wordCount\":441,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201210005824r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/\",\"name\":\"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201210005824r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"datePublished\":\"2020-12-10T17:03:13+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/#primaryimage\",\"url\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201210005824r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\",\"contentUrl\":\"https:\\\/\\\/cts.businesswire.com\\\/ct\\\/CT?id=bwnews&amp;sty=20201210005824r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/","og_locale":"en_US","og_type":"article","og_title":"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital - Market Newsdesk","og_description":"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital PARIS&#8211;(BUSINESS WIRE)&#8211; Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible) (Paris:SIGHT) (the &#8220;Company&#8221; or &#8220;GenSight&#8220;), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, announces today that it has received, in connection with its bond agreement entered with Kreos Capital VI (Expert Fund) LP (&#8220;Kreos&#8220;), the notification by Kreos of (i) the conversion of 50% of the convertible bonds of tranches A and B (at a price of \u20ac2.245 per share), (ii) the conversion of 50% of the additional convertible bonds of tranche B (at a price of \u20ac2.574 &hellip; Continue reading \"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/","og_site_name":"Market Newsdesk","article_published_time":"2020-12-10T17:03:13+00:00","og_image":[{"url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201210005824r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital","datePublished":"2020-12-10T17:03:13+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/"},"wordCount":441,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201210005824r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/","name":"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/#primaryimage"},"thumbnailUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201210005824r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","datePublished":"2020-12-10T17:03:13+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/#primaryimage","url":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201210005824r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en","contentUrl":"https:\/\/cts.businesswire.com\/ct\/CT?id=bwnews&amp;sty=20201210005824r1&amp;sid=flmnd&amp;distro=nx&amp;lang=en"},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/gensight-biologics-announces-the-partial-conversion-of-convertible-bonds-and-full-exercise-of-share-warrants-by-kreos-capital\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"GenSight Biologics Announces the Partial Conversion of Convertible Bonds and Full Exercise of Share Warrants by Kreos Capital"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397628","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=397628"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/397628\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=397628"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=397628"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=397628"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}